Terminated PHASE1 INTERVENTIONAL 1-arm NCT00426829

Proton Therapy and Bevacizumab for Primary Liver Tumors

Phase I Study of Proton Radiotherapy and Bevacizumab for Primary Liver Tumors

Sponsor: Genentech, Inc.

Conditions Cholangiocarcinoma Hepatocellular Carcinoma Liver Cancer

Interventions Bevacizumab Proton Radiation Therapy

Updated 5 times since 2017 Last updated: Jul 31, 2012 Started: May 31, 2007 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low Accural

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

Other Cholangiocarcinoma trials with similar outcome

Browse all Cholangiocarcinoma trials

A PHASE1 clinical study on Cholangiocarcinoma and Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Genentech, Inc. and has accumulated 5 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

May 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States